Background and Necessity

The Ministry of Food and Drug Safety (MFDS) recently announced new guidelines regarding the import of human drugs. With the surge in telemedicine and overseas drug purchases following the COVID-19 pandemic, a safe and reliable import system became necessary. This announcement aims to improve patient access and prevent illegal distribution.

PLAIR and Safe Importation Action Plan

The new guidelines include PLAIR (Pharmaceutical Logistics and Import Regulation) and the Safe Importation Action Plan. PLAIR refers to a framework for integrated management of drug logistics and import regulations. The Safe Importation Action Plan includes measures to ensure patient safety by detailing the verification of hazardous substances, labeling standards, and tracking systems.

Significance of the Personal Importation Policy

The Personal Importation Policy specifies the conditions under which patients can directly import drugs purchased from overseas. This opens the way to alleviate the cost burden of expensive treatments and expand access to treatments for rare diseases. However, the MFDS aims to minimize the risk of adverse effects by strengthening quality verification and legality confirmation procedures.

Market and Regulatory Outlook

This policy is expected to influence the diversification of drug supply chains and the market entry strategies of global pharmaceutical companies. Increased regulatory transparency will facilitate the entry of overseas manufacturers into the Korean market, and the demand for patient-centered, customized treatments is likely to increase. Therefore, the proportion of imported drugs and related regulatory environments may change significantly depending on the results of the policy implementation.